'Setback' for breast cancer drug
A cancer charity has expressed its disappointment after the health regulator said a new drug to treat breast cancer was “not value for money”.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units